[15] and under the brand names Wegovy and Kayshild for the treatment of metabolic-associated steatohepatitis (nonalcoholic steatohepatitis) and liver cirrhosis
Active Ingredient 3 Active ingredient is semaglutide
History of prior GI surgery, hypothyroidism, and certain medications that independently slow motility (opioids, anticholinergics) all compound the risk
"I eat the same five meals on repeat now," she said
Following high-profile reports in 2024 of an elevated risk of nonarteritic anterior ischemic optic neuropathy (NAION) in type 2 diabetes patients taking glucagonlike peptide-1 (GLP-1) receptor agonists seen at one facility (Massachusetts Eye and Ear), there remains a need to clarify the potential risk of ophthalmic complications from semaglutide exposure using multicenter data
Patients with Hashimoto's disease often have complex metabolic profiles, and the addition of Ozempic requires individualised evaluation